-
The Journal of Craniofacial SurgeryCystic hygroma is one type of the benign malformations and typically located in the neck, clavicle, and others, in children under the age of 5 years. However, the...
Cystic hygroma is one type of the benign malformations and typically located in the neck, clavicle, and others, in children under the age of 5 years. However, the incidence of giant cervicomediastinal giant cystic hygroma is very rare, especially in adulthood. Such a location and age make its diagnosis difficult because they are usually asymptomatic. Complete surgical resection seems impossible while multiple sites are involved. Herein, we present a case of giant cervicomediastinal cystic hygroma, describing the clinical presentation, radiographic features, and OK-432 sclerotherapy. In conclusion, repeated OK-432 sclerotherapy may be an effective treatment option in giant cervicomediastinal cystic hygroma. Pay close attention to patient's symptoms and vital signs, adjusting the OK-432 dose throughout the process.
Topics: Child; Humans; Adult; Child, Preschool; Picibanil; Lymphangioma, Cystic; Sclerotherapy; Neck; Clavicle
PubMed: 36409853
DOI: 10.1097/SCS.0000000000008692 -
The Journal of Dermatology May 1995
Topics: Adult; Antineoplastic Agents; Bursitis; Epidermal Cyst; Foot Diseases; Humans; Injections, Intralesional; Male; Picibanil; Recurrence
PubMed: 7673563
DOI: 10.1111/j.1346-8138.1995.tb03410.x -
Brazilian Journal of Otorhinolaryngology 2023This study aims to perform a meta-analysis to figure out the efficacy of OK-432 sclerotherapy between Macrocystic (MAC) lymphangiomas and Microcystic (MIC) lymphangiomas. (Meta-Analysis)
Meta-Analysis Review
OBJECTIVE
This study aims to perform a meta-analysis to figure out the efficacy of OK-432 sclerotherapy between Macrocystic (MAC) lymphangiomas and Microcystic (MIC) lymphangiomas.
METHODS
We conducted a systematic review and meta-analysis to clarify the relationship between OK-432 and lymphangiomas. PubMed and ISI Web of Science were searched from inception to May 2022. Joanna Briggs Institute (JBI) manual was used to evaluate the risk of bias. We calculated pooled Relative Risks (RR) and 95% Confidence Interval (95% CI) using random effects model to evaluate the relations between OK-432 and lymphangiomas.
RESULTS
A total of 11 studies (including 352 cases) about OK-432 sclerotherapy for lymphangioma were included in the current meta-analyses. The results suggested that the efficacy of OK-432 was significantly in MAC lesions than in MIC (RR=1.51, 95% CI 1.298-1.764), with significant moderate degrees of heterogeneity among 11 studies (I=51.2%, p=0.025). Subgroup analyses suggested that there was significant association in both retrospective studies (RR=1.26, 95% CI 1.03-1.53) and classification (by 1 cm) (RR=1.37, 95% CI 1.04-1.80) were associated with the efficacy of OK-432.
CONCLUSION
To our knowledge, our study represents the first meta-analysis examining the efficacy of OK-432 in the treatment of different types of LMs. However, the regional differences and the age differences of the subjects are the main limitations of this study and should be avoided in further research. Our results suggested that OK-432 sclerotherapy for macrocystic lymphangiomas was more effective.
Topics: Humans; Picibanil; Sclerotherapy; Retrospective Studies; Lymphangioma; Cysts; Treatment Outcome
PubMed: 37331237
DOI: 10.1016/j.bjorl.2023.03.007 -
Fetal Diagnosis and Therapy 2015Primary fetal hydrothorax (PFHT) is an uncommon condition with an estimated prevalence of 1 in 10,000/15,000 pregnancies. Therapeutic interventions include...
BACKGROUND
Primary fetal hydrothorax (PFHT) is an uncommon condition with an estimated prevalence of 1 in 10,000/15,000 pregnancies. Therapeutic interventions include thoracocentesis, thoraco-amniotic shunting (TAS), and pleurodesis using OK-432.
METHODS
A review of the literature was performed to identify all cases of PFHT treated with TAS and OK-432. All cases of PFHT referred to the Fetal Maternal Unit at Royal Prince Alfred Hospital between 2002 and 2012 were retrospectively reviewed. In the cohort of fetuses treated with OK-432, the main perinatal outcomes evaluated were termination of pregnancy, live birth, neonatal death, and fetal death in utero. Secondary outcomes included gestational age (GA) at diagnosis, GA at treatment, GA at resolution, birth weight, and GA at birth. The development of the children was screened using the Ages and Stages Questionnaires, Version 3 (ASQ-3, 2009).
RESULTS
Primary hydrothorax was diagnosed in 31 fetuses, of which 14 had treatment with OK-432. One pregnancy terminated after treatment with OK-432. Survival was 85% (11/13): 100% in fetuses treated with OK-432 without hydrops, and 78% in those treated with hydrops. This compares well to the cases of TAS in the literature with an average survival of 63%: 85% in fetuses without hydrops and 55% with hydrops. The mean GA at birth was 36(+4) weeks and mean birth weight 3,007 g. Eight of the 9 children screened with ASQ-3 scored well within the normal range.
CONCLUSION
OK-432 appears to be a valid treatment option in fetuses with PFHT, particularly in those diagnosed at early GAs.
Topics: Female; Fetal Diseases; Gestational Age; Humans; Hydrothorax; Male; Picibanil; Pregnancy; Prognosis; Retrospective Studies; Treatment Outcome; Ultrasonography, Prenatal
PubMed: 25721226
DOI: 10.1159/000363651 -
Surgical Neurology Mar 1987During the period from January 1981 to December 1983, two groups of a total of 51 patients (31 malignant astrocytomas, 17 glioblastomas, and 3 others) were treated with... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
During the period from January 1981 to December 1983, two groups of a total of 51 patients (31 malignant astrocytomas, 17 glioblastomas, and 3 others) were treated with radioimmunochemotherapy using nimustine hydrochloride (ACNU) plus Picibanil (OK-432) (group A) and radiochemotherapy with ACNU only (group B) in a randomized controlled study. Group A consisted of 24 patients and group B of 27 patients. The differences in the background of the two groups were not statistically significant. Survival curves of both groups were shown by the Kaplan-Meier method. The postoperative survival rate at 1 year and 3 years was 70% and 30%, respectively, equal in both groups, and the differences between groups A and B were not statistically significant by the Cox-Mantel test. The side effects seen in group B were most prominent in the bone marrow, and severe leukopenia occurred. However, in group A leukopenia was suppressed after 2 months. Immunologic parameters, such as the purified protein derivative skin reaction test, did not change, but the streptococcus pyogenes Su-strain polysaccharide skin-reaction test became more positive after therapy in group A.
Topics: Adult; Aged; Biological Products; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Glioma; Humans; Leukopenia; Male; Middle Aged; Nimustine; Nitrosourea Compounds; Picibanil; Random Allocation; Skin Tests
PubMed: 3544286
DOI: 10.1016/0090-3019(87)90039-5 -
Fetal Diagnosis and Therapy 2009To develop a model to study the fetal effects of intrapleural infusion of OK-432 (Picibanil), a pleurodesis agent derived from killed Gram-positive streptococci.
OBJECTIVE
To develop a model to study the fetal effects of intrapleural infusion of OK-432 (Picibanil), a pleurodesis agent derived from killed Gram-positive streptococci.
METHODS
OK-432 (0.1 mg, n = 5), or normal saline (n = 5) were infused over 20 min into the pleural space of chronically instrumented preterm fetal sheep at 0.7 gestation. Fetal physiological parameters, including breathing and nuchal activity were monitored in utero from 6 h before infusion until 12 h afterward, and fetuses were killed after 7 days recovery.
RESULTS
OK-432 was associated with transient suppression of fetal EEG activity, breathing and body movements from 3-6 h after infusion. Hypotension and hypoxia did not occur. At postmortem, local pleural adhesions were seen around the site of OK-432 infusion but not in saline treated fetuses.
CONCLUSIONS
Intrapleural administration of OK-432 is associated with marked but transient fetal behavioral effects. This model will enable preclinical investigation of the neural and cardiovascular safety of OK-432 at a clinical relevant stage of development.
Topics: Animals; Blood Pressure; Chylothorax; Fetus; Heart Rate, Fetal; Picibanil; Pleural Cavity; Respiration; Sheep
PubMed: 19776593
DOI: 10.1159/000235876 -
Lancet (London, England) Jun 1983
Topics: Ascites; Biological Products; Humans; Picibanil; Stomach Neoplasms; Streptococcus pyogenes
PubMed: 6134047
DOI: No ID Found -
Archivos de La Sociedad Espanola de... Jan 2012Lymphangioma is a malformation of the lymphatic system. The classic approach is surgery. We report a case of orbital lymphangioma in a girl who was given OK-432 to avoid...
INTRODUCTION
Lymphangioma is a malformation of the lymphatic system. The classic approach is surgery. We report a case of orbital lymphangioma in a girl who was given OK-432 to avoid surgery and its complications.
DISCUSSION
OK-432 is a lyophilized mixture of group A Streptococcus pyogenes which produces a fibrosis limited to the lesion with a high cure rate. The main advantages are the easy intra-lesional application. with no scars and or damage of closed areas. Its main disadvantage is a significant local inflammatory reaction.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Agents; Blepharoptosis; Eyelid Diseases; Female; Hematoma; Humans; Lymphangioma; Magnetic Resonance Imaging; Orbital Neoplasms; Picibanil; Sclerosing Solutions; Treatment Failure
PubMed: 22248653
DOI: 10.1016/j.oftal.2011.05.022 -
Clinical Otolaryngology and Allied... Apr 2000The treatments previously used for lymphangiomas of the head and neck in children-surgery and intralesional injection of sclerosants-are associated with significant...
The treatments previously used for lymphangiomas of the head and neck in children-surgery and intralesional injection of sclerosants-are associated with significant morbidity. A new treatment-intralesional injection of OK-432-was used for lymphangiomas of the head and neck in 11 children. The results were total shrinkage in two, marked shrinkage in two, slight shrinkage in five and no response in two. The results were not affected by previous surgery nor by whether aspiration prior to injection was possible. There were no recurrences in those children in whom shrinkage occurred and no child had subsequent surgery following injection. The results of this series support those of previous series showing that OK-432 injection is an effective and safe treatment for lymphangiomas of the head and neck in children.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Routes; Female; Head and Neck Neoplasms; Humans; Infant; Injections; Lymphangioma; Male; Picibanil; Tomography, X-Ray Computed; Treatment Outcome
PubMed: 10816217
DOI: 10.1046/j.1365-2273.2000.00338.x -
Archives of Otolaryngology--head & Neck... Nov 1996To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas. (Clinical Trial)
Clinical Trial
OBJECTIVE
To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas.
DESIGN
Nonrandomized trial; follow-up, 4 to 29 months.
SETTING
Academic tertiary referral medical center.
PATIENTS
Six children with presumed lymphangiomas; age range at initial treatment, 1 month to 7 years 10 months.
INTERVENTION
Fluoroscopically guided cyst aspiration, cystography, and injection of OK-432.
OUTCOME MEASURES
Clinical and radiographic comparisons before and after therapy.
RESULTS
Complete response in 2 macrocystic lymphangiomas; no response in 3 microcystic lymphangiomas; and no response in 1 venous malformation.
CONCLUSION
OK-432 sclerotherapy may be effective treatment for macrocystic lymphangiomas.
Topics: Child; Child, Preschool; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Infant; Lymphangioma, Cystic; Male; Picibanil; Radiography; Sclerosing Solutions; Sclerotherapy
PubMed: 8906054
DOI: 10.1001/archotol.1996.01890230041009